- 1 Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2
- 2 Omicron BA. 2 variant infection, severe illness, and death
- 3 Zhuoying Huang^{1†}, Shuangfei Xu^{2†}, Jiechen Liu¹, Linlin Wu¹, Jing Qiu¹, Nan Wang¹, Jia
- 4 Ren¹, Zhi Li¹, Xiang Guo¹, Fangfang Tao³, Jian Chen³, Donglei Lu⁴, Xiaodong Sun^{1*},
- 5 Weibing Wang^{2,5}*
- ⁶ ¹Institute of Immunization, Shanghai Municipal Center of Disease Control and Prevention,
- 7 Shanghai 200336, China
- 8 ²School of Public Health, Shanghai Institute of Infectious Disease and Biosecurity, Fudan
- 9 University, Shanghai 200032, China
- 10 ³Institute of Infectious Diseases, Shanghai Municipal Center of Disease Control and
- 11 Prevention, Shanghai 200336, China
- ⁴Division of Health Risk Factors Monitoring and Control, Shanghai Municipal Center of
- 13 Disease Control and Prevention, Shanghai 200336, China
- ⁵Key Laboratory of Public Health Safety of Ministry of Education, Fudan University,
- 15 Shanghai 200032, China
- 16
- [†] These authors contributed equally to this work
- 18
- 19 * Corresponding:
- 20 Dr. Xiaodong Sun, Shanghai Municipal Center of Disease Control and Prevention, 1380
- 21 Western Zhongshan Road, Shanghai 200336, China (e-mail: sunxiaodong@scdc.sh.cn).
- 22 Dr. Weibing Wang, Department of Epidemiology, School of Public Health, Fudan University,
- 23 138 Yi Xue Yuan Road, Shanghai 200032, China (e-mail: wwb@fudan.edu.cn)
- 24

26 ABSTRACT

27 Background Limited data are available on effectiveness of inactivated and Ad5-nCoV 28 COVID-19 vaccines in real-world use - especially against Omicron variants in SARS-CoV-2 29 infection-naïve population. During an outbreak in Shanghai's SARS-CoV-2 infection-naïve 30 population, we evaluated vaccine effectiveness (VE) against Omicron infection, severe or 31 critical COVID-19, and COVID-19-related death. 32 **Methods** A matched case-control study was conducted among people aged ≥ 3 years between 33 2 December 2021 through 13 May 2022. Cases were SARS-CoV-2 infected individuals, 34 individuals with severe/critical COVID-19, or COVID-19-related deaths. Controls were

35 selected from consecutively test negative individuals at the same time as cases were 36 diagnosed and were exact-matched on year-of-age, gender, birthplace, illness onset date, and 37 residency district in ratios of 1:1 with infected individuals and 4:1 with severe/critical 38 COVID-19 and COVID-19-related deaths.

39

40 Results Our study included 612597 documented SARS-CoV-2 infections, among which 1485 41 progressed to severe or critical illness and 568 died. Inactivated vaccine was 16.3% (95% CI: 42 15.4%-17.2%) effective against infection, 88.6% (95% CI: 85.8%-90.9%) effective against 43 severe/critical COVIID-19 and 91.7% (95% CI: 86.9%-94.7%) against COVID-19 death. 44 Ad5-vectored vaccine was 13.2% (95% CI: 10.9%-15.5%) effective against infection and 45 77.9% (95% CI: 15.6%-94.2%) effective against severe/critical COVIID-19. Booster 46 vaccination with inactivated vaccines enhanced protection against severe COVID-19 (92.7%, 47 95% CI: 90.1%-94.6%) and COVID-19 death (95.9%, 95% CI: 91.4%-98.1%). Inactivated 48 VE against infection began to wane 12 weeks after the last dose but two- and three-dose 49 sustained high protection levels (>80%) against severe/critical illness and death.

50

51 **Conclusions** Our real-world study found high and durable two- and three-dose inactivated 52 VE against Omicron-associated severe/critical illness and death across all age groups, but 53 lower effectiveness against Omicron infection. High direct protection from severe/fatal 54 Omicron COVID-19 provided by inactivated vaccines, and a consequent potential reduction 55 in health-care utilization, reinforces the critical importance of full-series vaccination and 56 timely booster dose administration for all eligible individuals.

57

58 Keywords: COVID-19; Vaccines Effectiveness; Case-Control Study; Inactivated Vaccine

59 **INTRODUCTION**

60 The Omicron BA. 2 SARS-CoV-2 variant of concern was first detected in the United States in November of 2021 and has subsequently spread globally.¹ Sequencing of virus isolates 61 from 129 COVID-19 patients between late February 2022 and May 2022 showed that 62 Omicron BA. 2 was the dominate sub-lineage in Shanghai². Omicron BA. 2 differs by 63 approximately 40 mutations from the original Omicron lineage, BA. 1, and has a growth 64 65 advantage over BA.1.³ While studies are ongoing to understand the reasons for this growth advantage, initial data suggest that BA.2 appears more transmissible than BA. 1, which 66 67 currently remains the most common Omicron sub-lineage reported. Rodent models suggest 68 that infectivity and pathogenicity of Omicron/BA. 2 variant are similar to Omicron/BA. 1's. 4,5 69

70

71 Studies in Israel, the United Kingdom, and the United States have demonstrated that primaryseries and booster vaccination with mRNA vaccines protect against SARS-CoV-2 infection, 72 with greater protection from COVID-19 related hospitalizations and severe outcomes ⁶⁻⁸ 73 which is also seen against Omicron outcomes. 9-11 Studies have also reported reduced 74 neutralizing antibody activity against Omicron.¹² Fewer data are available on real-world 75 76 vaccine effectiveness (VE) of inactivated and adenovirus type 5 vectored vaccine, especially 77 against Omicron. A Singapore study before Omicron became prevalent reported that 78 compared with BNT162b2, subjects who received inactivated whole virus vaccines were more likely to be infected with SARS-CoV-2.¹³ An ecological VE study in Hong Kong found 79 80 that three doses of either BNT162b2 or CoronaVac provided substantial protection against 81 severe COVID-19 (VE>95%) and death (VE>96%) caused by confirmed Omicron variant infection.¹⁴ 82

83

84 In Shanghai, COVID-19 vaccination started in February 2021 among residents 18-59 years 85 old, in March 2021 among residents 60-75 years of age, in May 2021 for individuals 76 years 86 and older, and in September 2021 for children 3-17 years of age. Booster vaccination started 87 in November 2021 for residents \geq 18 years; children are not yet eligible for boosters. As of 88 May 2022, there is no approved COVID-19 vaccine for children <3 years in China. One out 89 of every four doses of COVID-19 administered globally has been CoronaVac. Despite its 90 global importance, limited evidence is available on the efficacy or effectiveness of this 91 vaccine.

93 Between 2 December 2021 and 13 May 2022, a total of 618,019 individuals tested RT-PCR-

94 positive for SARS-CoV-2 infection. By that time, over 90% of the population aged \geq 3 years

95 were reported to have received a primary series, and 47% received a booster dose. With its

96 SARS-CoV-2-infection-naïve population, Shanghai provided a nearly-unique outbreak setting

97 to estimate real-world, vaccine-only-induced inactivated and Ad5-vectored COVID-19 VE

98 against documented SARS-CoV-2 Omicron infection, severe or critical COVID-19, and

99 COVID-19 related death.

100 METHODS

101 Study Setting and Study Participants

102 The study was conducted among people living in Shanghai, a provincial-level municipality in 103 China with a resident population of more than 25 million people. Everyone living in 104 Shanghai - citizens, foreigners, and immigrants - underwent several rounds of SARS-CoV-2 105 real time polymerase chain reaction (RT-PCR) testing between 2 December 2021 and 13 May 106 2022. Complete demographic (age, gender, birthplace, and residency district), vaccination, 107 and RT-PCR testing data were available to public health officials and study investigators. 108 Individuals with negative RT-PCR SARS-CoV-2 tests who had tested positive before 2 109 December 2021 were excluded. Children less than three years of age were not vaccine-110 eligible and were excluded.

111

Controls were selected from consecutively test negative individuals at the same time as cases were diagnosed. The size of the potential control group was 25.18 million people receiving several round city-wide nucleic acid amplification testing (NAAT), and RT-PCR testing was universal regardless of COVID-19 associated symptoms.

116 Study Design

We used a matched case-control design for data extraction. Cases were individuals with documented SARS-CoV-2 infection, severe or critical COVID-19, or COVID-19-related death. Infection-only cases were matched 1:1 with controls on year-of-age, gender, birthplace (Shanghai/other place), date of testing, and residency district; severe or critical COVID-19 cases and COVID-19-related death cases were matched 1:4 on year-of-age, gender, birthplace, date of illness onset, and residency district (Figure 1). We matched each case to unique controls without replacement. When there are more than one case-control pair available, we

selected the first (for infection-only cases) or first four (for severe/critical and fatal cases)
eligible individuals. We constructed two subsets to analyze separate VEs of inactivated
vaccines (subset 1) and Ad5 vectored vaccine (subset 2) against each of the three outcomes
(figures S1 and S2).

128 Infections and Outcomes

129 PCR testing for SARS-CoV-2 is available in public hospitals and private laboratories 130 throughout China. Since 10 March 2022, Shanghai conducted several rounds of SARS-CoV-2 131 tests, each involving more than 25 million people. Severity of disease for all SARS-CoV-2 132 infections was assessed in any of 48 COVID-19 designated hospitals in accordance with the Diagnosis and Treatment Protocol for COVID-19 (Trial Version 9).¹⁵ We included three 133 134 outcomes in our study: documented SARS-CoV-2 infection, severe/critical COVID-19, and 135 COVID-19-related death. Documented SARS-CoV-2 infection was confirmed by a positive 136 RT-PCR test. For adult cases, severe illness must meet any of the following criteria: a) 137 respiratory distress (Respiration Rate $[RR] \ge 30$ breaths per min), b) oxygen saturation $\le 93\%$ 138 at rest, c) arterial partial pressure of oxygen/fraction of inspired oxygen \leq 300mmHg. 139 Additionally, cases with chest imaging that shows obvious lesion progression within 24-48 140 hours > 50% shall be managed as severe illness. For child cases, severe illness must meet any 141 of the following criteria: a) Persistent high fever over three days, b) tachypnea ($RR \ge 60$ 142 BPM for infants aged below 2 months; $RR \ge 50$ BPM for infants aged 2-12 months; $RR \ge 40$ 143 BPM for children aged 1-5 years, and RR \geq 30 BPM for children >5 years), independent of 144 fever and crying, c) oxygen saturation ≤93% on finger pulse oximeter taken at rest, d) labored 145 breathing (moaning, nasal fluttering, infrasternal, supraclavicular and intercostal retraction), 146 cyanosis, and intermittent apnea, e) lethargy and convulsion, f) difficulty feeding and signs of 147 dehydration. Critical illness must meet any of the following criteria: a) respiratory failure and 148 requiring mechanical ventilation; b) shock, c) With other organ failure that requires ICU care. 149 COVID-19 related death is assessed by medical institutions.

150

Data on all confirmed and asymptomatic cases between 2 December 2021 and 13 May 2022
were extracted from the National Notifiable Diseases Registry System (NNDRS).

153 Vaccination Data

154 The Shanghai Group Immunization System captures all vaccine administrations and is 155 updated daily. This immunization information system is the repository of nearly all vaccinees'

156 records, and includes name, national identification number, vaccine type, vaccination date, 157 vaccination dose, vaccination site, and vaccine manufacturer. This system is linked to the 158 National Immunization Program Information System, which adds documented national 159 identification-matching COVID-19 vaccinations received outside of Shanghai. Immunization 160 histories were verified manually with records for subjects three years and older who had an 161 unknown national identification number. NAAT data were linked to individual vaccination 162 records using national identification number and name. Vaccination data were extracted and 163 matched to cases and controls on 13 May 2022. Figure S3 shows the process of vaccination history retrieval. 164

165

166 Vaccination status was categorized into four levels in accordance with national technical 167 recommendations for COVID-19 vaccination: (1) unvaccinated - either no history of 168 COVID-19 vaccination before the last SARS-CoV-2 exposure date; (2) partial vaccination – 169 either one dose of inactivated vaccine; or two doses of inactivated vaccine but receiving the 170 second dose within 14 days before the last SARS-CoV-2 exposure date; two doses of 171 recombinant protein vaccine (three doses are recommended for primary vaccination); or one 172 dose of adenovirus vector vaccine or three doses of recombinant protein vaccine but with the 173 most recent dose within 14 days before the last SARS-CoV-2 exposure date; (3) full primary 174 vaccination - either two doses of inactivated vaccine, one dose of adenovirus vector vaccine, 175 or three doses of recombinant protein (CHO cell) vaccine with the most recent doses 14 days 176 or more before the last SARS-CoV-2 exposure date and with no booster dose; or two doses of 177 inactivated vaccine with one booster dose of inactivated vaccine, adenovirus vector vaccine, 178 or recombinant protein (CHO cell) vaccine within 7 days before the last SARS-CoV-2 179 exposure date; or two doses of adenovirus vector vaccine within 7 days before the last 180 exposure date; or (4) booster vaccination – either two doses of Ad5-vectored vaccine with 181 the second dose 7 days or more before the last exposure date; or two doses of inactivated 182 vaccine and one booster dose of inactivated vaccine, adenovirus vector vaccine, or 183 recombinant protein vaccine 7 days or more before the last exposure date.

184

Vaccination intervals were stratified by dose and interval (in weeks) post vaccination at <2, 3-12, 13-24, 25-36, 37+ weeks after the first dose, <2, 3-12, 13-24, 25-36, 37+ weeks after the second dose, and <2, 3-12, 13-24, 25+ weeks after the third dose. Intervals (in days) were defined as the number of days between the onset date of infection and the date of last vaccination minus 2 days, which was then converted into weeks. Detailed variable definitions

are in table S1. Additionally, we performed a sensitivity analysis in which intervals (in days)
were defined as the number of days between testing positive date and the date of last
vaccination minus 7 days.

193 Statistical Analysis

194 Non-normally distributed continuous variables were expressed as medians (interquartile 195 ranges, IQR), and categorical variables were expressed as counts and proportions. 196 Conditional logistic regression was used to estimate the odds ratio (OR) of vaccination 197 among cases and controls, with documented SARS-CoV-2 infection, severe or critical 198 COVID-19, and COVID-19 related death as dependent variables. Vaccination status was the 199 independent variable and VE was defined as 1 minus the matched OR. Vaccination status was 200 defined using the date of onset and date of last vaccination, as above. Analyses were stratified 201 by age category, gender, and vaccine type (inactivated vaccine, adenovirus vector vaccine, 202 and recombinant protein vaccine). Matching were conducted with the use of JAVA, and 203 Analyses were performed with the use of RStudio 2022.02.3+492.

204 **RESULTS**

205 Study Population

There were 612597 SARS-CoV-2 RT-PCR confirmed cases in the study, among which 1485 progressed into severe or critical illness and 568 died (Table 1). The most common age for infection was 40-59 years of age (37.3%); the most common age for severe/critical COVID-19 and COVID-19 death was 80 years and older (58.6% of severe/critical COVID-19 and 69.9% of COVID-19 deaths). Due to the exact matching, the demographic characteristics of controls and cases were the same (Table 1).

212 Vaccination Status

Figure 2 shows vaccination status of the control group over time and by age group. At the beginning of the study period, 82.7% people received at least one dose of a COVID-19 vaccine, with the majority 18-59-years old. The prevalence of the adult-focused booster dose increased from 11.9% to 49.0%. Full and partial coverage among adults aged 80 years and above was low and stable at approximately 15%. Figure 2 also shows the cumulative incidence of documented SARS-CoV-2 infection (250.9 per 10,000), of which the majority were 18-59 years old. Since March 12, a series of emergency epidemic prevention measures

were implemented in Shanghai, including mass NAATs, citywide lockdowns, home quarantine of residents, isolation of cases, centralized quarantine of close contacts, and closed-loop management. The rapid spread of Omicron led to temporary suspension of vaccination starting in March 2022.

224 Vaccine Effectiveness

225 COVID-19 vaccines provided some protection against SARS-CoV-2 infection in all age 226 groups (overall VE: 16.0%, 95% CI: 15.1%, 17.0%), while in age group 40-59 years, 227 protection was lower (VE: 7.5%, 95%CI: 5.5%, 9.5%). COVID-19 vaccines provided high 228 effectiveness against severe/critical illness (VE: 88.6%, 95% CI: 85.8%, 90.8%) and COVID-229 19 related death (VE: 91.6%, 95% CI: 86.8%, 94.6%). There was little difference in VE by 230 gender. Estimated VEs for full primary vaccination and booster doses against severe/critical 231 illness were 83.8% (95% CI: 79.0%, 87.5%) and 92.8% (95% CI: 90.2%, 94.7%), 232 respectively, and against COVID-19 related death were 85.7% (95% CI: 75.6%, 91.6%) and 233 96.2% (95% CI: 92.0%, 98.2%), respectively. Inactivated vaccine was 16.3% (95% CI: 234 15.4%, 17.2%) effective against infection, 88.6% (95% CI: 85.8%, 90.9%) effective against 235 severe/critical COVIID-19 and 91.7% (95% CI: 86.95%, 94.7%) against COVID-19 death. 236 Ad5-vectored vaccine was 13.2% (95% CI: 11.0%, 15.5%) effective against infection and 237 77.9% (95% CI: 15.6%, 94.2%) effective against severe/critical COVIID-19. See Table 2.

238

We used subset 1 and subset 2 to estimate vaccine specific VEs. Figure 3 shows VEs of inactivated vaccine against SARS-CoV-2 infection, severe/critical illness, and COVID-19 related death; respective overall VEs were 16.6% (95% CI: 15.6%, 17.5%), 88.5% (95% CI:85.6%, 90.7%) and 91.7 (95% CI: 86.8%, 94.8%). Booster vaccination with inactivated vaccine enhanced the protection for both severe outcome (VE: 92.7%, 95% CI: 90.1%, 94.6%) and death (VE: 95.9%, 95% CI: 91.4%, 98.1%).

245

Considering time between the last dose and SARS-Co2 exposure, figure 4 shows that the VE of inactivated vaccines against SARS-CoV-2 infection was 15.7% (95% CI:10.8%, 20.4%) 3-

248 12 weeks after first dose. Two-dose inactivated vaccine offered 16.9% (95% CI: 13.2%,

249 20.4%) protection for infection after 12 weeks, and three-dose offered 19.2% (95% CI: 18.2%,

250 20.3%) after 24 weeks, then both subsequently becoming lower. Full series and boosted VEs

for severe/critical illness and COVID-19 death remained >80%.

253 For SARS-CoV-2 infection, estimated VEs of Ad5-vectored vaccine were 39.3% (95% CI: -

254 17.9%, 68.8%) at 3-12 weeks after a first dose and 16.0% (95% CI: 1.5%, 28.4%) at 13-

255 24weeks after a second dose. Due to the small number of severe/critical illness and death

256 cases in subset 2, VEs by time interval were not able to be estimated for this vaccine (Table

257 S2).

258 Sensitivity Analysis

Tables S3 and S4 show the sensitivity analyses of VEs which were consistent with results displayed in table 2 and figure 3.

261 **DISCUSSION**

262 From 2 December 2021 through 13 May 2022, during an Omicron BA2.2-predominant wave 263 of COVID-19 in Shanghai, China, we used detailed, individual-level, records-documented 264 COVID-19 vaccination status; universal, population-wide individual-level SARS-CoV-2 RT-265 PCR testing results; and individual-level clinical evaluations to estimate real-world 266 effectiveness of inactivated and Ad5-vectored vaccines in a largely infection-naïve population. 267 Our matched case-control study showed that the inactivated vaccines were highly effective 268 against severe or critical COVID-19 and COVID-19-related death, findings that underscore 269 the potential of the vaccines to save lives and substantially reduce demands on healthcare 270 system. Inactivated vaccine was 16.3% effective against Omicron infection, 88.6% effective 271 against severe/critical COVIID-19 and 91.7% against COVID-19 death. Ad5-vectored 272 vaccine was 13.2% effective against infection and 77.9% effective against severe/critical 273 COVIID-19. Booster-dose protection against severe/critical COVID-19 was 92.7% and 274 against COVID-19 death was 95.9%. Protection from infection waned after 12 weeks, but 275 primary series and booster-dose protection was sustained above 80% for at least 36 weeks 276 from the last dose.

277

We found that VE against Omicron infection was lower than efficacy against ancestral-strain SARS-CoV-2 symptomatic infection observed in a phase 3 clinical trial (72.8% and 78.1%) and a real-world, pre-Omicron VE study in Chile (83.5%). ^{16,17} However, our VE estimates for the two predominant inactivated (Sinovac and Sinopharm) vaccines were very high in age-group analyses, notably among persons 80 years of age or older, and independent of time since vaccination. The lower VE against Omicron infection in younger adults may be partly

due to a higher force of infection in working-age adults or differences in willing to be
 vaccinated (although vaccination rates were very high in all ages under 60 years). ¹⁸

286

287 Booster vaccination was 93% and 96% effective against severe illness and death, somewhat 288 higher than full primary series vaccination VEs. We found that inactivated VE against severe 289 illness and COVID-19 associated death to be higher than respective VEs observed in Brazil 290 $(77.6\% \text{ and } 83.9\%)^{19,20}$ and Chile $(90.3\% \text{ and } 86.3\%)^{17}$, in which the circulating SARS-291 CoV-2 strains predated Omicron emergence. Clinical trials have shown inactivated vaccine 292 efficacies to be lower than that of mRNA vaccines, but there are fewer real-world data on two- and three-dose inactivated VE against Omicron infection or hospitalization. ^{16,21} The 293 Hong Kong ecological study found an initial VE from two doses of inactivated COVID-19 294 295 vaccine against Omicron infection to be 17.9% with rapid waning - similar to our results.¹⁴ 296 Also similar to our findings, the Hong Kong scientists showed inactivated VE against severe 297 illness and death to be very high - 74% for primary vaccination and 98% for boosted 298 vaccination. Our study extended the time frame for duration of inactivated VE, showing 299 sustained protection against severe COVID-19 and COVID-19 death through 36 weeks.

300

301 Omicron BA. 2 COVID-19 disease is less severe than Delta and BA. 1 associated COVID-19 disease²², resulting in a lower risk of hospitalization and severe illness. Indeed, over 85% of 302 303 the SARS-CoV-2 infections reported from Shanghai by China's National Health Commission 304 were asymptomatic (http://www.nhc.gov.cn/xcs/xxgzbd/gzbd_index.shtml). Milder infections 305 may reflect increased replication of Omicron in the upper versus lower respiratory tract - a 306 phenomenon that could contribute to more efficient transmission, leading to a higher absolute 307 number of hospitalizations. Omicron infection enhances preexisting immunity elicited by 308 vaccines but, on its own, may not confer broad protection against non-Omicron variants in unvaccinated individuals²³. A study demonstrated that inactivated vaccines elicited SARS-309 310 CoV-2-specific memory T/B cell immunity, which are important for robust recall of 311 protective responses against viral replication, and therefore induce longer-term protection against severe illness and deaths. 24,25 However, Omicron's immune evasion, including 312 313 evasion of mucosal immunity allows Omicron to escape existing antibodies and increase risk of reinfection, leading to a surge in infections.^{26,27} Evaluations of vaccines that have potential 314 315 to block infection/transmission (e.g., the inhaled Ad5-vectored vaccine by CanSino that may provide mucosal immunity) are especially important. ^{28,29} 316

318 We estimated the VEs of Ad5-vectored vaccine to be 39.3% at 3-12 weeks after a first dose 319 but 16.0% at 13-24 weeks after a second dose. A study in Brazil reported that whereas waning 320 of VE against symptomatic COVID-19 was observed \geq 90 days after homologous and 321 heterologous boosters, waning against severe COVID-19 was only observed after a 322 homologous booster, suggesting a need for adjustment of vaccination strategies - e.g. 323 heterologous boosters for those who have received 2 doses of inactivated vaccines as their primary series. ²⁰ None of the current COVID-19 vaccines block infection/transmission; our 324 325 results also show that the vaccines we evaluated cannot make a permanent barrier to contain 326 the Omicron transmission in community, despite high vaccine coverage.

327

328 Our study has strengths. The setting was a COVID-19 outbreak in the large and diverse 329 socioeconomic population of Shanghai in which 2.7% of the population was infected by the 330 Omicron BA. 2 variant of SARS-CoV-2 before the outbreak was stopped by public health and 331 social interventions. In addition, because COVID-19 is being managed as a Level-1 332 infectious disease, all infected individuals are compulsively reported to the disease prevention 333 and control system daily. Infections are always confirmed with additional RT-PCR testing, 334 making diagnostic misclassification highly unlikely. The cases in our study were from a 335 community of 25 million people, repeatedly screened for infection using RT-PCR. We used 336 individual level exact matching to control for potential confounding factors of age, sex, 337 residential district, birthplace, and illness onset time. Finally, our study measured VE levels in 338 an infection-naïve population, allowing assessment of nearly pure vaccine-induced, real-339 world VE, avoiding distortion from hybrid immunity.

340

341 Limitations of our study include possible misclassification of disease status, which was 342 judged by the COVID-19 designated hospitals. The definitions of severe/critical COVID-19 343 are objective, the misclassification of severe illness is unlikely because disease severity for all 344 SARS-CoV-2 infection is made in accordance with the Diagnosis and Treatment Protocol for 345 COVID-19. A second limitation is the lack of information on comorbidities, precluding 346 analyses by comorbidity. We attempted to reduce potential bias by matching on 347 sociodemographic characteristics. In addition, the younger-aged population is at highest risk 348 of infection and may also have greater willingness or opportunity to get vaccinated, possibly 349 leading to an underestimate VE among working-age adults. Third, the study was conducted 350 during a strict lockdown - especially after April 4 - which may have biased the estimation of 351 VE (e.g. more likely to have null hypothesis) by decreasing the force of infection (attack rate

among susceptibles). However, the universal NAAT screenings and exact matching that included district helped ensure similar exposure risk of cases and controls and our sensitivity analysis showed no meaningful differences in results. Finally, the number of Ad5-vectorred vaccine doses used in Shanghai was too small for subgroup analyses and for estimating VE against death.

357 CONCLUSION

Our study showed high and durable two- and three-dose inactivated VE against severe/critical COVID-19 and death caused by Omicron infection across all age group, but with lower effectiveness against Omicron infection. Everyone eligible should be vaccinated; individuals eligible for booster doses should receive timely boosters; improving coverage among the elderly is especially important. The vaccines being used in China are highly effective where it matters most - preventing severe illness and death – and are most effective when boosted.

364

365 **REFERENCES**

- 366 1. World Health Organization. Statement on Omicron sublineage BA. 2. 2022.
 367 <u>https://www.who.int/news/item/22-02-2022-statement-on-omicron-sublineage-BA. 2</u> (accessed
 368 February 22 2022).
- 369 2. Zhang X, Zhang W, Chen S. Shanghai's life-saving efforts against the current omicron wave of

370 the COVID-19 pandemic. *Lancet (London, England)* 2022: S0140-6736(22)00838-8.

- 371 3. Viana R, Moyo S, Amoako DG, et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron
 372 variant in southern Africa. *Nature* 2022; **603**(7902): 679-86.
- 4. Uraki R, Kiso M, Iida S, et al. Characterization and antiviral susceptibility of SARS-CoV-2
 Omicron/BA. 2. *Nature* 2022.
- 5. Yu J, Collier AY, Rowe M, et al. Neutralization of the SARS-CoV-2 Omicron BA. 1 and BA. 2
 Variants. *The New England journal of medicine* 2022; **386**(16): 1579-80.
- 377 6. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass
 378 Vaccination Setting. *N Engl J Med* 2021; **384**(15): 1412-23.
- 379 7. Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2
- 380 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following
- 381 a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
- 382 *The Lancet* 2021; **397**(10287): 1819-29.
- 383 8. Pawlowski C, Lenehan P, Puranik A, et al. FDA-authorized mRNA COVID-19 vaccines are
- 384 effective per real-world evidence synthesized across a multi-state health system. *Med (N Y)* 2021; **2**(8):

- 386 9. Andrews N, Stowe J, Kirsebom F, et al. Covid-19 Vaccine Effectiveness against the Omicron
 387 (B.1.1.529) Variant. *N Engl J Med* 2022; **386**(16): 1532-46.
- 388 10. Chemaitelly H, Yassine HM, Benslimane FM, et al. mRNA-1273 COVID-19 vaccine
- 389 effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nat
- 390 *Med* 2021; **27**(9): 1614-21.
- 391 11. Wright BJ, Tideman S, Diaz GA, French T, Parsons GT, Robicsek A. Comparative vaccine
- 392 effectiveness against severe COVID-19 over time in US hospital administrative data: a case-control
- 393 study. *The Lancet Respiratory Medicine* 2022.
- 12. Cao Y, Wang J, Jian F, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing
 antibodies. *Nature* 2022; **602**(7898): 657-63.
- 396 13. Premikha M, Chiew CJ, Wei WE, et al. Comparative Effectiveness of mRNA and Inactivated
- Whole Virus Vaccines against COVID-19 Infection and Severe Disease in Singapore. *Clin Infect Dis*2022.
- 399 14. McMenamin ME, Nealon J, Lin Y, et al. Vaccine effectiveness of two and three doses of
 400 BNT162b2 and CoronaVac against COVID-19 in Hong Kong. *medRxiv* 2022: 2022.03.22.22272769.
- $\mathbf{B}_{1110202} \text{ and } \mathbf{C}_{0101a} \text{ vac against } \mathbf{C}_{011} \mathbf{C}_{11} \mathbf{D}_{11} \mathbf{D}_{11} \mathbf{D}_{12} \mathbf{D}_{22} \mathbf{D}_{22}$
- 401 15. National Health Commission & State Administration of Traditional Chinese Medicine. Diagnosis
- 402 and Treatment Protocol for COVID-19 (Trial Version 9). 2022.403 http://www.gov.cn/zhengce/zhengceku/2022-
- 404 03/15/5679257/files/49854a49c7004f4ea9e622f3f2c568d8.pdf (accessed March 14 2022).
- 405 16. Al Kaabi N, Zhang Y, Xia S, et al. Effect of 2 Inactivated SARS-CoV-2 Vaccines on
- 406 Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. *JAMA* 2021; 326(1): 35407 45.
- 408 17. Jara A, Undurraga EA, González C, et al. Effectiveness of an Inactivated SARS-CoV-2 Vaccine
 409 in Chile. *N Engl J Med* 2021; **385**(10): 875-84.
- 410 18. Nasreen S, Chung H, He S, et al. Effectiveness of COVID-19 vaccines against symptomatic
- 411 SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario. *Nat Microbiol* 2022;
 412 7(3): 379-85.
- 413 19. Ranzani OT, Hitchings MDT, Dorion M, et al. Effectiveness of the CoronaVac vaccine in older
- 414 adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control
- 415 study. *Bmj* 2021; **374**: n2015.
- 416 20. Ranzani OT, Hitchings MDT, de Melo RL, et al. Effectiveness of an Inactivated Covid-19
- 417 Vaccine with Homologous and Heterologous Boosters against the Omicron (B.1.1.529) Variant.
- 418 *medRxiv* 2022: 2022.03.30.22273193.

^{385 979-92} e8.

- 419 21. Wilder-Smith A, Mulholland K. Effectiveness of an Inactivated SARS-CoV-2 Vaccine. The New
- 420 *England journal of medicine* 2021; **385**(10): 946-8.
- 421 22. Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical severity of the SARS-CoV-2
- 422 omicron variant in South Africa: a data linkage study. *Lancet* 2022; **399**(10323): 437-46.
- 423 23. Suryawanshi RK, Chen IP, Ma T, et al. Limited Cross-Variant Immunity after Infection with the
- 424 SARS-CoV-2 Omicron Variant Without Vaccination. *medRxiv* 2022.
- 425 24. Liu Y, Zeng Q, Deng C, et al. Robust induction of B cell and T cell responses by a third dose of
- 426 inactivated SARS-CoV-2 vaccine. *Cell Discov* 2022; **8**(1): 10.
- 427 25. Ahmed SF, Quadeer AA, McKay MR. SARS-CoV-2 T Cell Responses Elicited by COVID-19
- 428 Vaccines or Infection Are Expected to Remain Robust against Omicron. *Viruses* 2022; **14**(1).
- 429 26. Ao D, Lan T, He X, et al. SARS-CoV-2 Omicron variant: Immune escape and vaccine
- 430 development. *MedComm* (2020) 2022; **3**(1): e126.
- 431 27. Lapuente D, Fuchs J, Willar J, et al. Protective mucosal immunity against SARS-CoV-2 after
- 432 heterologous systemic prime-mucosal boost immunization. *Nat Commun* 2021; **12**(1): 6871.
- 433 28. Schubert M, Bertoglio F, Steinke S, et al. Human serum from SARS-CoV-2-vaccinated and
- 434 COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant. *BMC Med*
- 435 2022; **20**(1): 102.
- 436 29. Bartsch YC, Tong X, Kang J, et al. Omicron variant Spike-specific antibody binding and Fc
- 437 activity are preserved in recipients of mRNA or inactivated COVID-19 vaccines. Sci Transl Med 2022;
- 438 **14**(642): eabn9243.
- 439 Figure
- 440 Figure 1. Participant enrollment flowchart.
- 441

442 Figure 2. Vaccination status in the control group and cumulative documented SARS-CoV-2 infections 443 by age grouping in Shanghai, 1 December 2021 through 13 May 2022. Also shown are public health 444 and social measures implemented during the study period. Vaccination status for control group was 445 from a total of 623,420 controls, including 1:1 match with infected individuals and 4:1 with severe/critical 446 COVID-19 and COVID-19-related deaths. Data for cumulative incidence of SARS-CoV-2 infection was 447 provided by Shanghai Health Commission, and numerator was the daily number of cumulative 448 infected cases and denominator was the corresponding population size from the seventh National 449 Census. 450

- 451 Figure 3. Vaccine effectiveness of inactivated vaccines against documented SARS-CoV-2 infection,
- 452 severe or critical illness, and COVID-19 death in the matched case-control study.

453

454	Figure 4. VE (%) of inactivated vaccine against documented SARS-CoV-2 infection, severe or critical
455	illness, and death by doses and time interval. Data are presented with VEs (black points) and 95%
456	confidence intervals (color zones). To visualize the trend of vaccine effectiveness (dark blue lines), we
457	smoothed the VE results by performing three spline interpolations of the calculated data points for the
458	corresponding time period. Small sample sizes of corresponding cells lead to the wide confidence
459	intervals. Eight individuals had severe/critical illness and two died within first-doses intervals.
460	
461	

462 List of abbreviations

- 463 VE, vaccine effectiveness
- 464 CI: Confidence interval
- 465 RT-PCR: real time polymerase chain reaction
- 466 NAAT: nucleic acid amplification testing
- 467 RR: Respiration Rate
- 468 NNDRS: National Notifiable Diseases Registry System
- 469 IQR: interquartile ranges
- 470 OR: odds ratio

471 Ethics approval and consent to participate

The study was approved by the Ethical Review Committee in the Shanghai Center forDisease Control and Prevention (approval number: 2022-20).

474 **Consent for publication**

475 Not applicable.

476 **Funding**

This work was supported by the Science and Technology Commission of Shanghai
Municipality (Grant No. 22YJ1400200), Shanghai New Three-year Action Plan for Public

479 Health (Grant No. GWV-10.1-XK16), Shanghai "Rising Stars of Medical Talents" Youth

- 480 Development Program, Youth Medical Talents-Public Health Leadership Program (Grant No.
- 481 SHWSRS (2020)_87), study on the sero-epidemiology and transmission risk of COVID-19

482 (Grant No. 20JC1410200), and Shanghai Municipal Science and Technology Major Project

483 (Grant No. ZD2021CY001).

484 Availability of data and materials

The data that support the findings of this study are available from the Z.H. and X.S., upon reasonable request.

487 **Competing interests**

488 There are no conflicts of interest for all authors.


489 Author contributions

490 Z.H. conceptualized the study, collected data and drafted the manuscript. S.X. performed 491 analysis and drafted the manuscript. J.L. performed data clean and controlled quality. L.W. 492 assisted with study design. J.Q., N.W., J.R., Z.L., F.T., and D.L. collected data. X.G., and J.C. 493 reviewed manuscript. X.S. conceptualized the study, assisted with the analysis, and reviewed 494 and edited the manuscript. W.W. assisted with the analysis and reviewed and edited the 495 manuscript.

496 Acknowledgement


We sincerely appreciate all the valuable comments and suggestions from Dr. Lance Rodewald,
Dr. Zundong Yin, Dr. Zhijie An, Dr. Huaqing Wang, Dr. Wenzhou Yu, and Dr. Lin Tang from
Chinese Center for Disease Control and Prevention, which allowed us to greatly improve the
quality of the manuscript.





505 506

Figure 1. Participant enrollment flowchart.



vaccination course E Booster vaccination E Full vaccination Partial vaccination - Cumulative SRAS-CoV-2 infection

507 508 Figure 2. Vaccination status in the control group and cumulative documented SARS-CoV-2 infections 509 by age grouping in Shanghai, 1 December 2021 through 13 May 2022. Also shown are public health 510 and social measures implemented during the study period. Vaccination status for control group was 511 from a total of 623,420 controls, including 1:1 match with infected individuals and 4:1 with severe/critical 512 COVID-19 and COVID-19-related deaths. Data for cumulative incidence of SARS-CoV-2 infection was 513 provided by Shanghai Health Commission, and numerator was the daily number of cumulative 514 infected cases and denominator was the corresponding population size from the seventh National 515 Census.

Group	Cases	Controls	VE (95% CI), %		VE (95% CI), %
Omicron infection			1		
Overall	-		•		16.6 (15.6, 17.
By gender					
Male	262,183 (84.1)	268,735 (86.3)	•		19.7 (18.4, 21.)
Female		210,095 (80.9)	•		13.4 (12.0, 14.)
By age group					
3-17 year-old	25,874 (72.8)	26,856 (75,5)	-		20.2 (16.8, 23.
18-39 year-old		177,444 (90.9)			-1.5 (-3.8, 0.7)
40-59 year-old		193,240 (91.8)			8.0 (6.0, 10.0)
60-79 year-old	70,212 (63.3)				29.7 (28.3, 31.)
80+ year-old	2,243 (11.7)	3,186 (16.6)			36.9 (32.8, 40.
By resident region	2,245 (11.7)	3,100 (10.0)			30.3 (32.0, 40.
Urban	162 020 /76 5)	170,565 (79.7)			22 0 /20 7 22
					22.0 (20.7, 23.)
Rural	304,120 (65.1)	308,265 (86.3)			11.9 (10.5, 13.)
By vaccination course	10 100 10 11	10 000 10 11	Sec.		
Partial vaccination	13,436 (2.4)	12,266 (2.1)	1. The second		5.8 (3.2, 8.2)
Full vaccination		199,004 (34.8)	•		15.9 (14.8, 16.
Booster vaccination	258,790 (45.3)	267,560 (46.8)	•		17.9 (16.9, 18.
Severe/critical illness					
Overall	-	-		-	88.5 (85.6, 90.)
By gender					
Male	120 (14.7)	1,444 (44.3)			87.7 (84.1, 90.)
Female	45 (6.9)	617 (23.8)			90.2 (84.9, 93.0
By age group					
3-17 year-old	0 (0.0)	4 (100.0)			
18-39 year-old	4 (40.0)	32 (80.0)			88.6 (42.1, 97.)
40-59 year-old	42 (50.0)	305 (90.8)			95.7 (89.1, 98.)
60-79 year-old	90 (18.0)	1,266 (63.4)		-	89.3 (85.9, 91.)
80+ year-old	29 (3.3)	454 (13.1)			80.5 (70.7, 87.0
By resident region	25 (3.5)	434 (13.1)		•	00.5 (10.1, 01.)
Urban	81 (10.0)	1,096 (33.9)		-	89 2 /84 1 01
Rural					88.2 (84.1, 91.)
	84 (12.8)	965 (36.9)		1	88.8 (84.4, 91.)
By vaccination course	a (a a)	07 (4 4)			
Partial vaccination	9 (0.6)	67 (1.1)			76.7 (51.7, 88.
Full vaccination	92 (6.3)	829 (14.2)			83.4 (78.4, 87.3
Booster vaccination	64 (4.4)	1,165 (19.9)		•	92.7 (90.1, 94.0
Death					
Overall	-	-			91.7 (86.8, 94.3
By gender					
Male	23 (7.8)	421 (35.6)			90.1 (83.6, 94.0
Female	6 (2.3)	181 (17.3)			95.7 (86.2, 98.)
By age group					
3-17 year-old	-	-			
18-39 year-old	1 (50.0)	8 (100.0)			
40-59 year-old	5 (31.3)	56 (87.5)			92.1 (71.6, 97.0
60-79 year-old	18 (12.3)	319 (54.6)			89.9 (82.1, 94.)
80+ year-old	5 (1.3)	219 (13.9)			94.7 (85.4, 98.
By resident region	0 (1.0)	210 (10.0)		1	54.7 (05.4, 50.
Urban	12 (3.8)	313 (25.1)			93.5 (86.5, 96.)
Rural					
	17 (6.9)	289 (29.5)			89.9 (81.6, 94.
By vaccination course	0 (0 ()	00 /4 0			77 0 /4 4 0 4 0
Partial vaccination	2 (0.4)	23 (1.0)			77.8 (4.1, 94.8
Full vaccination	19 (3.4)	245 (11.0)		•	86.6 (76.6, 92.3
Booster vaccination	8 (1.4)	334 (15.0)			95.9 (91.4, 98.

518 519

Figure 3. Vaccine effectiveness of inactivated vaccines against documented SARS-CoV-2 infection,

severe or critical illness, and COVID-19 death in the matched case-control study.




Figure 4. VE (%) of inactivated vaccine against documented SARS-CoV-2 infection, severe or critical illness, and death by doses and time interval. Data are presented with VEs (black points) and 95% confidence intervals (color zones). To visualize the trend of vaccine effectiveness (dark blue lines), we smoothed the VE results by performing three spline interpolations of the calculated data points for the corresponding time period. Small sample sizes of corresponding cells lead to the wide confidence intervals. Eight individuals had severe/critical illness and two died within first-doses intervals.